Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review

Authors

  • Gabrielle van der Velde,

    Corresponding author
    1. Toronto Health Economics and Technology Assessment Collaborative and Institute for Work and Health, Toronto, Ontario, Canada
    • THETA Collaborative, Leslie L. Dan Pharmacy Building, University of Toronto, 6th Floor, Room 658, 144 College Street, Toronto, Ontario, M5S 3M2 Canada

    Search for more papers by this author
  • Ba' Pham,

    1. Toronto Health Economics and Technology Assessment Collaborative, Toronto, Ontario, Canada
    Search for more papers by this author
  • Márcio Machado,

    1. Toronto Health Economics and Technology Assessment Collaborative, Toronto, Ontario, Canada
    Current affiliation:
    1. GlaxoSmithKline, Rio de Janeiro, Brazil
    Search for more papers by this author
  • Luciano Ieraci,

    1. Toronto Health Economics and Technology Assessment Collaborative, Toronto, Ontario, Canada
    Search for more papers by this author
  • William Witteman,

    1. Toronto Health Economics and Technology Assessment Collaborative, Toronto, Ontario, Canada
    Search for more papers by this author
  • Claire Bombardier,

    1. Toronto Health Economics and Technology Assessment Collaborative and Institute for Work and Health, Toronto, Ontario, Canada
    Search for more papers by this author
    • Dr. Bombardier has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from AstraZeneca, Pfizer, Biogen Idec, PESI Healthcare, and Roche, and (more than $10,000 each) from Abbott Canada and Abbott International, Wyeth (Merck), and Schering (Merck).

  • Murray Krahn

    1. Toronto Health Economics and Technology Assessment Collaborative, Toronto, Ontario, Canada
    Search for more papers by this author

Ancillary